{"schema_version":"secwatch.filing_event.v1","accession":"0001664710-24-000075","form_type":"8-K","ticker":"KROS","cik":"0001664710","company_name":"Keros Therapeutics, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.026610+00:00","generated_at":"2026-05-31T06:38:45.217084+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Keros closes screening for Phase 2 TROPOS trial in PAH; expects topline data in Q2 2025","bullets":["Phase 2 TROPOS trial of cibotercept (KER-012) for PAH has closed screening.","Company expects to complete enrollment by end of September 2024.","Topline data now expected in Q2 2025, earlier than previously anticipated.","CEO Jasbir Seehra cited strong demand and rapid enrollment as catalysts."],"urls":{"canonical":"https://secwatch.observer/filing/0001664710-24-000075","json":"https://secwatch.observer/filing/0001664710-24-000075.json","markdown":"https://secwatch.observer/filing/0001664710-24-000075.md","text":"https://secwatch.observer/filing/0001664710-24-000075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000075/0001664710-24-000075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1664710/000166471024000075/kros-20240903.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:38:45.217084+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}